126 related articles for article (PubMed ID: 37805050)
61. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
62. The economic burden of overactive bladder (OAB) and its effects on the costs associated with other chronic, age-related comorbidities in the United States.
Durden E; Walker D; Gray S; Fowler R; Juneau P; Gooch K
Neurourol Urodyn; 2018 Jun; 37(5):1641-1649. PubMed ID: 29464813
[TBL] [Abstract][Full Text] [Related]
63. Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder.
Latini JM; Giannantoni A
Expert Opin Pharmacother; 2011 May; 12(7):1017-27. PubMed ID: 21473706
[TBL] [Abstract][Full Text] [Related]
64. Adverse Childhood Experiences in Women With Overactive Bladder or Interstitial Cystitis/Bladder Pain Syndrome.
Komesu YM; Petersen TR; Krantz TE; Ninivaggio CS; Jeppson PC; Meriwether KV; Dunivan GC
Female Pelvic Med Reconstr Surg; 2021 Jan; 27(1):e208-e214. PubMed ID: 33369968
[TBL] [Abstract][Full Text] [Related]
65. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder.
Tang DH; Colayco DC; Khalaf KM; Piercy J; Patel V; Globe D; Ginsberg D
BJU Int; 2014 Mar; 113(3):484-91. PubMed ID: 24528881
[TBL] [Abstract][Full Text] [Related]
66. Prevalence of xerostomia with or without overactive bladder symptoms.
Ito K; Inoue M; Nishii H; Matsumoto T
Low Urin Tract Symptoms; 2021 Apr; 13(2):224-229. PubMed ID: 33034141
[TBL] [Abstract][Full Text] [Related]
67. Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries.
Sura S; Shiozawa A; Ng D; Aparasu RR
J Am Med Dir Assoc; 2021 Jun; 22(6):1300-1306. PubMed ID: 33071158
[TBL] [Abstract][Full Text] [Related]
68. Urothelial Dysfunction and Chronic Inflammation in Diabetic Patients with Overactive Bladder.
Wang CC; Kuo HC
Low Urin Tract Symptoms; 2017 Sep; 9(3):151-156. PubMed ID: 27018971
[TBL] [Abstract][Full Text] [Related]
69. Association between overactive bladder treatment and falls among older adults.
Jayadevappa R; Chhatre S; Newman DK; Schwartz JS; Wein AJ
Neurourol Urodyn; 2018 Nov; 37(8):2688-2694. PubMed ID: 29806158
[TBL] [Abstract][Full Text] [Related]
70. Relationship between overactive bladder and irritable bowel syndrome: a large-scale internet survey in Japan using the overactive bladder symptom score and Rome III criteria.
Matsumoto S; Hashizume K; Wada N; Hori J; Tamaki G; Kita M; Iwata T; Kakizaki H
BJU Int; 2013 Apr; 111(4):647-52. PubMed ID: 23106867
[TBL] [Abstract][Full Text] [Related]
71. A non-interventional cross-sectional re-contact study investigating the relationship between overactive bladder and frailty in older adults in Japan.
Yoshida M; Satake S; Ishida K; Tanaka Y; Ukai M
BMC Geriatr; 2022 Jan; 22(1):68. PubMed ID: 35062875
[TBL] [Abstract][Full Text] [Related]
72. Evaluation of Urine Choline Levels in Women With and Without Overactive Bladder Syndrome.
Sheyn D; Hijaz AK; Hazlett FE; Dawodu K; El-Nashar S; Mangel JM; Petrikovets A; Mahajan ST
Female Pelvic Med Reconstr Surg; 2020 Oct; 26(10):644-648. PubMed ID: 30212388
[TBL] [Abstract][Full Text] [Related]
73. Cerebral White Matter Disease and Response to Anti-Cholinergic Medication for Overactive Bladder in an Age-Matched Cohort.
Sheyn D; Mahajan ST; Hijaz A; Slopnick E; Chapman G; El-Nashar S; Mangel JM
Int Urogynecol J; 2019 Oct; 30(10):1755-1761. PubMed ID: 31152187
[TBL] [Abstract][Full Text] [Related]
74. Unraveling the interplay between dyskinesia and overactive bladder symptoms in Parkinson's disease: a comprehensive cohort study based on the long-term follow-up database of Parkinson's disease.
Jin H; Du Y; Yan J; Zhang J; Cheng X; Mao C; Chen J; Liu CF
BMC Neurol; 2024 Mar; 24(1):94. PubMed ID: 38468238
[TBL] [Abstract][Full Text] [Related]
75. Association between metformin use and risk of prostate cancer and its grade.
Margel D; Urbach D; Lipscombe LL; Bell CM; Kulkarni G; Austin PC; Fleshner N
J Natl Cancer Inst; 2013 Aug; 105(15):1123-31. PubMed ID: 23853056
[TBL] [Abstract][Full Text] [Related]
76. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis.
Sicras-Mainar A; Rejas J; Navarro-Artieda R; Aguado-Jodar A; Ruiz-Torrejón A; Ibáñez-Nolla J; Kvasz M
Int Urogynecol J; 2014 Apr; 25(4):485-92. PubMed ID: 24196653
[TBL] [Abstract][Full Text] [Related]
77. Comparing adherence and persistence across 6 chronic medication classes.
Yeaw J; Benner JS; Walt JG; Sian S; Smith DB
J Manag Care Pharm; 2009; 15(9):728-40. PubMed ID: 19954264
[TBL] [Abstract][Full Text] [Related]
78. Impact of Coexisting Overactive Bladder in Medicare Patients With Dementia on Clinical and Economic Outcomes.
Caplan EO; Abbass IM; Suehs BT; Ng DB; Gooch K; van Amerongen D
Am J Alzheimers Dis Other Demen; 2019; 34(7-8):492-499. PubMed ID: 30966757
[TBL] [Abstract][Full Text] [Related]
79. [Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis].
Krunal Vishavadia KV; Sandip Solanki SS; Hiren Prajapati HP; Madhu Sharma MS
Urologiia; 2023 May; (2):66-72. PubMed ID: 37401707
[TBL] [Abstract][Full Text] [Related]
80. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial.
Khullar V; Cambronero J; Angulo JC; Wooning M; Blauwet MB; Dorrepaal C; Martin NE
BMC Urol; 2013 Sep; 13():45. PubMed ID: 24047126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
